Struggling with frequent bathroom trips or a weak urine stream? Learn how to manage BPH with personalized care, from ...
Chicago, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The global benign prostatic hyperplasia surgical treatment market was valued at US$ 10.5 billion in 2024 and is expected to reach us$ 16.5 billion by 2033, ...
Discover a study showing TURP combined with TUIBN improves outcomes and reduces complications in small-volume BPH patients.
A hospital has said it performed a record number of pioneering procedures in one day in a bid to help curb its backlog.
Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. The Food and Drug Administration (FDA) has approved Entadfi ...
Discover a study showing how urethra-sparing robot-assisted simple prostatectomy preserves ejaculatory function while ...
June 18, 2010 (UPDATED June 21, 2010) — The US Food and Drug Administration (FDA) has approved a single-capsule formulation of 0.5-mg dutasteride and 0.4-mg tamsulosin (Jalyn; GlaxoSmithKline) for ...
WGMB/WVLA Baton Rouge on MSN
Baton Rouge General first hospital to offer robotic system for prostate treatment
The hospital is the first in Baton Rouge to offer Aquablation therapy with an AI-powered robotic system to treat benign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback